Sermorelin

Sermorelin is a linear 29-residue peptide whose N-terminal sequence preserves the receptor-binding determinants of full-length hGRF while omitting the C-terminal tail that drives proteolytic clearance — a structural simplification that has made it a useful probe for receptor-engagement studies. The molecule binds the GHRH receptor on pituitary somatotrophs, a class B G-protein-coupled receptor whose signaling cascade has been extensively documented in the literature. Pharmacokinetic descriptors documented in published investigations include a short plasma half-life on the order of minutes under standard parenteral paradigms, with rapid clearance via peptidases. Interaction profile in published work covers cAMP signaling activation, somatotroph membrane potential changes, and pulsatile growth-hormone release in feedback-control models — all reported categorically. Structural confirmation is established by mass spectrometry molecular-ion match and HPLC-validated purity on each Certificate of Analysis.

Experimental domains documented in the published literature include GHRH-receptor binding studies, somatotroph-cell signaling assays, growth-hormone-axis feedback-control investigations, in-vitro pituitary-cell stimulation paradigms, and comparative work alongside other growth-hormone-releasing peptide classes. Investigators have also characterized sermorelin in studies of receptor desensitization and in feedback-loop modeling where the molecule serves as a defined activator of GHRH signaling. Its use in laboratory research extends to structure-activity work where N-terminal fragment variants are compared against the parent 29-residue sequence. The reference standard is supplied for these and equivalent in-vitro experimental contexts only, with no associated guidance for human, clinical, or veterinary application. Researchers should consult primary literature and institutional review processes when designing context-specific protocols.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C149H246N44O42S empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.